Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05456698

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

A single-center, single-arm, open-label, interventional, phase II clinical trial to evaluate the efficacy and safety of InO in B-ALL achieved CR/CRi after 1L induction chemotherapy with positive minimal residual disease.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Acute Lymphocytic Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New diagnosed B-ALL in hematologic complete remission (CR) after 1L induction chemotherapy with MRD positive. Molecular disease or MRD is defined by a value of at least of 10-4 (0.01%) by multicolor flow cytometry.
  • Age ≥18 years
  • ECOG PS score: 0 to 2
  • Functions of the main organs are normal, if the following criteria are met:
  • Total bilirubin (BIL) ≤ 1.5 × upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN
  • Serum creatinine ≤ 1.5 × ULN
  • Creatinine clearance ≥ 30 ml/min
  • No active or co-existing malignancy with a life expectancy of less than 12 months
  • Patients are voluntarily enrolled into the study and have good compliance, and the Informed Consent Form (ICF) needs to be signed.

Exclusion criteria

  • Mixed lineage leukemia
  • Clinically significant liver disease such as history of veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS)
  • Patients with severe and / or uncontrolled diseases, such as:
  • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months before randomization, severe uncontrolled arrhythmias; uncontrolled blood pressure (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg)
  • Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis
  • Known to be human immunodeficiency virus positive (HIV+)
  • Active and uncontrolled disease/infection as judged by the treating physician
  • Active central nervous system (CNS) or extramedullary disease
  • Patients who have other malignant tumors at the same time; patients who are evaluated by the investigator to have concomitant diseases that seriously endanger the safety of the patients or affect the patients to complete the study
  • Pregnant or nursing women
  • Unable or unwilling to sign the consent form
  • Monoclonal antibodies therapy within 2 weeks before study entry
  • Radiotherapy or cancer chemotherapy (except for induction chemo) or any investigational drug within 2 weeks before study entry
  • Patients who have severe allergies (≥ grade 3) to active ingredients and any excipients of InO
  • Patients in other situations who are evaluated by the investigator to be ineligible

Treatment and study plan

Inotuzumab ozogamicin

Drug

Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.

Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity.

Other names: CMC-544

Primary outcomes

  1. MRD negativity rate within the first treatment cycle

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

    MRD negativity is defined as no presence of small numbers of leukemic cells detected by the flow cytometry after remission

Secondary outcomes

  1. Complete MRD response rates

    Time frame: At the end of Cycle 1 and Cycle 2, respectively (each cycle is 28 days)

    Complete MRD response is defined as no presence of small numbers of leukemic cells detected by the flow cytometry after remission

  2. Duration of MRD negativity rate

    Time frame: From enrollment to the end of Cycle 1 or Cycle 2, which achieves MRD negative first (each cycle is 28 days)

    The duration of MRD response was analyzed as the time from onset of MRD negativity until MRD or hematological relapse or date of last confirmation of negative MRD status.

  3. MRD level variation from baseline to post cycle 1, cycle 2 in patients with detectable MRD, respectively

    Time frame: From enrollment to the end of Cycle 1 and Cycle 2, respectively (each cycle is 28 days)

    The variation of MRD level from baseline to post cycle 1, cycle 2, respectively

  4. Relapse-free Survival (RFS)

    Time frame: Up to 5 years from enrollment

    RFS is defined as the time from the date of CR until the date of relapse or death

  5. Overall Survival (OS)

    Time frame: Up to 5 years from enrollment

    OS is defined as the time from enrollment to date of death due to any cause.

Sponsors and collaborators

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China

Other

Registry information

Official study title

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy: A Phase 2, Open-label, Single-arm, Single-center Trial

Important dates

Study start
2022
Primary completion
2025
Study completion
2030
First posted
Jul 13, 2022
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.